EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Radiotheranostics in oncology: Making precision medicine possible

Eric O Aboagye iD, Tara D Barwick, Uwe Haberkorn

CA: A Cancer Journal for Clinicians · 2023

DOI: 10.3322/caac.21768 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CA: A Cancer Journal for Clinicians, 2023. Verfasst von Eric O Aboagye und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Neuroendocrine Tumors. Die Arbeit wurde bisher 101-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A quintessential setting for precision medicine, theranostics refers to a rapidly evolving field of medicine in which disease is diagnosed followed by treatment of disease‐positive patients using tools for the therapy identical or similar to those used for the diagnosis. Against the backdrop of only‐treat‐when‐visualized , the goal is a high therapeutic index with efficacy markedly surpassing toxicity. Oncology leads the way in theranostics innovation, where the approach has become possible with the identification of unique proteins and other factors selectively expressed in cancer versus healthy tissue, advances in imaging technology able to report these tissue factors, and major understanding of targeting chemicals and nanodevices together with methods to attach labels or warheads for imaging and therapy. Radiotheranostics —using radiopharmaceuticals—is becoming routine in patients with prostate cancer and neuroendocrine tumors who express the proteins PSMA (prostate‐specific membrane antigen) and SSTR2 (somatostatin receptor 2), respectively, on their cancer. The palpable excitement in the field stems from the finding that a proportion of patients with large metastatic burden show complete and partial responses, and this outcome is catalyzing the search for more radiotheranostics approaches. Not every patient will benefit from radiotheranostics; but, for those who cross the target‐detected line, the likelihood of response is very high.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsNeuroendocrine TumorsMaleHumansPrecision MedicineRadiopharmaceuticalsMedical Oncology

Stichwörter der Autor:innen

metastatic cancermolecularly targeted therapiesnuclear medicinepharmacologypositron emission tomographyradioisotopesradiotheranosticstheranostics audit trail

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
  • Department of Imaging, Imperial College Healthcare National Health Service Trust, Hammersmith Hospital, London, UK.
  • Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
  • Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center Heidelberg, Heidelberg, Germany.
  • Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany.

ORCID-Profile: Eric O Aboagye

Förderung

  • Medical Research Council

Zitieren

APA

Aboagye, E. O., Barwick, T. D., & Haberkorn, U. (2023). Radiotheranostics in oncology: Making precision medicine possible. CA: A Cancer Journal for Clinicians. https://doi.org/10.3322/caac.21768

Vancouver

Aboagye EO, Barwick TD, Haberkorn U. Radiotheranostics in oncology: Making precision medicine possible. CA: A Cancer Journal for Clinicians. 2023. doi:10.3322/caac.21768

BibTeX
@article{Aboagye2023,
  author = {Aboagye, Eric O and Barwick, Tara D and Haberkorn, Uwe},
  title = {Radiotheranostics in oncology: Making precision medicine possible},
  journal = {CA: A Cancer Journal for Clinicians},
  year = {2023},
  doi = {10.3322/caac.21768}
}
Kostenlos starten →